Targeting Ferroptosis and SRRM1 Overcomes Gemcitabine Resistance in Pancreatic Cancer
Researchers discover that inhibiting the splicing regulator SRRM1 activates ferroptosis to overcome gemcitabine resistance in pancreatic cancer models.
Tag: Gemcitabine resistance
Lab-grown gallbladder cancer organoids reproduce tumor genetics and predict chemotherapy response
Patient-derived gallbladder cancer organoids faithfully reproduced tumor genetics and showed drug sensitivities that tracked with patient survival in a preliminary ...
PLA2G2A fuels gallbladder cancer stemness and immune suppression
A new Cellular Oncology study shows that the enzyme PLA2G2A drives gallbladder cancer progression by promoting cancer stemness through PLA2R1, ...
AI Reads Bladder Cancer Slides and Pinpoints RTN3 Behind Chemotherapy Resistance
A multimodal AI model built from routine pathology slides predicts bladder cancer survival and led researchers to RTN3, which drives ...
Hypoxia-Driven Mitochondrial Enzyme Helps Pancreatic Cancer Evade Ferroptosis and Resist Gemcitabine
A new study links tumor hypoxia to ferroptosis suppression via SQOR-mediated coenzyme Q reduction, offering a potential strategy to overcome ...
Scientists Link a DNA-Building Enzyme to Fat Rewiring and Chemotherapy Failure in Pancreatic Cancer
A new study identifies RRM2 as a gene that connects nucleotide metabolism and SREBP1/FASN-driven lipid remodeling to gemcitabine resistance in ...
Glutamine Boosts Gemcitabine Resistance in Pancreatic Cancer
In an increasingly cancer-conscious world, new research findings are pointing towards a promising therapeutic strategy to tackle one of the ...
POPULAR NEWS
-
How Parkinson Disease Genetics Is Guiding Precision Medicine and Targeted Therapies
-
Study Analyzes NBA Return Rates After Major Lower-Extremity Tendon Surgeries
-
Zinc Oxide Coating Enhances Wear and Corrosion Resistance of Titanium Alloy
-
Staggered Antibiotic Delivery Overcomes Bacterial Nutrient-Driven Tolerance in Lab Tests